FindTrial
Sign In

Safety evaluation and effect of consumption of health product containing the combined extract of Khao Kum and Dill on the alterations of clinical symptoms and ischemic stroke biomarkers in transient ischemic attack and ischemic stroke patients

Safety evaluation and effect of consumption of health product containing the combined extract of Khao Kum and Dill on the alterations of clinical symptoms and ischemic stroke biomarkers in transient ischemic attack and ischemic stroke patients

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20201224001
Enrollment
60
Registered
2020-12-24
Start date
2021-03-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

transient ischemic attack Ischemic stroke Brain Supplement Khao Kum Dill transient ischemic attack Ischemic stroke

Interventions

Subjects are received the placebo product which has same color and smell look like product containing the combined extract of Khao Kum and Dill ,Subjects are received product containing the combined e
Placebo Comparator Dietary Supplement,Experimental Dietary Supplement,Experimental Dietary Supplement
medication plus placebo,medication plus product containing the combined extract of Khao Kum and Dill 600 mg/day,medication plus product containing the combined extract of Khao Kum and Dill 1200 mg/day

Sponsors

AGRICULTURAL RESEARCH DEVELOPMENT AGENCY (PUBLIC ORGANIZATION)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Acute ischaemic stroke within the past 5-10 days that caused hemiparesis or hemiplegia 2.Aged between 18 years and 85 years 3.Fugl-Meyer motor scale (FMMS) scores of 55 or less at baseline

Exclusion criteria

Exclusion criteria: 1.Post rt-PA 2.Severe post-stroke disability (NIHSS score >20) 3.Previous stroke with motor deficit, comprehension deficits (aphasia) Previous depression or MADRS score of more than 19; taking antidepressant drugs, monoamine oxidase inhibitors, neuroleptic drugs, or benzodiazepines during the month before inclusion 4.Undergoing carotid endarterectomy 5.Pregnancy 6.Major diseases that would prevent follow-up. Enrolment, follow-up

Design outcomes

Primary

MeasureTime frame
The changes of hematological and clinical chemistry parameters 6 weeks laboratory—

Secondary

MeasureTime frame
Vascular cell adhesion molecule1(VCAM-1) 6 weeks ELISA Kit ,Matrix metalloproteinases 9 (MMP-9) 6 weeks ELISA Kit ,VonWillebrand Factor (VWF) 6 weeks ELISA Kit ,S100β 6 weeks ELISA Kit ,safety evaluation and side effect 6 weeks Questionair,electrocardiogram 6 weeks electrocardiography equipment,NIHSS score 6 weeks Questionair,Stool examination (PH, Lactobacillus spp., Bifidobacterium spp. and Short chain fatty acid) 6 weeks laboratory—

Countries

Thailand

Contacts

Public ContactSomsak Tiamkao

Khon Kaen University

somtia@kku.ac.th0810504626

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026